- Home
- PAVM vs ATHA Comparison
PAVM vs ATHA Comparison
Compare PAVM & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAVM
- ATHA
- Stock Information
- Founded
- PAVM 2014
- ATHA 2011
- Country
- PAVM United States
- ATHA United States
- Employees
- PAVM N/A
- ATHA N/A
- Industry
- PAVM Medical/Dental Instruments
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- PAVM Health Care
- ATHA Health Care
- Exchange
- PAVM Nasdaq
- ATHA Nasdaq
- Market Cap
- PAVM 12.0M
- ATHA 10.6M
- IPO Year
- PAVM 2016
- ATHA 2020
- Fundamental
- Price
- PAVM $0.59
- ATHA $0.30
- Analyst Decision
- PAVM Strong Buy
- ATHA Buy
- Analyst Count
- PAVM 1
- ATHA 4
- Target Price
- PAVM $19.00
- ATHA $11.25
- AVG Volume (30 Days)
- PAVM 155.9K
- ATHA 241.5K
- Earning Date
- PAVM 08-11-2025
- ATHA 07-31-2025
- Dividend Yield
- PAVM N/A
- ATHA N/A
- EPS Growth
- PAVM N/A
- ATHA N/A
- EPS
- PAVM 0.96
- ATHA N/A
- Revenue
- PAVM $1,993,000.00
- ATHA N/A
- Revenue This Year
- PAVM N/A
- ATHA N/A
- Revenue Next Year
- PAVM $455.63
- ATHA N/A
- P/E Ratio
- PAVM $0.62
- ATHA N/A
- Revenue Growth
- PAVM N/A
- ATHA N/A
- 52 Week Low
- PAVM $0.55
- ATHA $0.22
- 52 Week High
- PAVM $1.90
- ATHA $3.67
- Technical
- Relative Strength Index (RSI)
- PAVM 41.35
- ATHA 49.17
- Support Level
- PAVM $0.59
- ATHA $0.29
- Resistance Level
- PAVM $0.63
- ATHA $0.32
- Average True Range (ATR)
- PAVM 0.04
- ATHA 0.02
- MACD
- PAVM -0.00
- ATHA -0.00
- Stochastic Oscillator
- PAVM 16.81
- ATHA 24.77
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.